CTKB

Cytek Biosciences Inc

Add to Watchlist

Advanced Chart

2.670

-0.010(-0.370%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.680

Open

2.660

VWAP

2.63

Vol

1.44M

Mkt Cap

338.18M

Low

2.520

Amount

3.80M

EV/EBITDA(TTM)

Total Shares

131.27M

78.74M

EV/OCF(TTM)

3.70

P/S(TTM)

1.77

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

59.23M

+3.06%

0.060

-48.03%

53.25M

+3.41%

0.030

-46.24%

46.68M

+0.13%

0.010

-231.58%

Estimates Revision

The market is revising Downward the revenue expectations for Cytek Biosciences, Inc. (CTKB) for FY2025, with the revenue forecasts being adjusted by -4.81% over the past three months. During the same period, the stock price has changed by -49.72%.

Revenue Estimates for FY2025

Revise Downward

-4.81%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-18.52%

In Past 3 Month

Stock Price

Go Down

-49.72%

In Past 3 Month

4 Analyst Rating

167.04% Upside

Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 7.13 USD with a low forecast of 4.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

1 Sell

Hold

167.04% Upside

Current: 2.670

Low

4.50

Averages

7.13

High

9.00

167.04% Upside

Current: 2.670

Low

4.50

Averages

7.13

High

9.00

Stephens & Co.

Mason Carrico

Buy

Reiterates

2025-03-19

Reason

Stephens & Co.

Mason Carrico

Price Target

2025-03-19

Reiterates

Buy

Reason

Piper Sandler

David Westenberg

Buy

Maintains

$8.5 → $8

2025-03-04

Reason

Piper Sandler

David Westenberg

Price Target

$8.5 → $8

2025-03-04

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on Cytek Biosciences to $8 from $8.25 following quarterly results. The firm keeps an Overweight rating on the shares.

Piper Sandler

David Westenberg

Buy

Maintains

$8 → $8.5

2024-11-11

Reason

Piper Sandler

David Westenberg

Price Target

$8 → $8.5

2024-11-11

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Cytek Biosciences to $8.50 from $8 following quarterly results. The firm keeps an Overweight rating on the shares.

Piper Sandler

David Westenberg

Buy

Maintains

$8.5 → $8

2024-08-13

Reason

Piper Sandler

David Westenberg

Price Target

$8.5 → $8

2024-08-13

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cytek Biosciences Inc (CTKB.O) is -273.00, compared to its 5-year average forward P/E of 93.84. For a more detailed relative valuation and DCF analysis to assess Cytek Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

93.84

Current PE

-273.00

Overvalued PE

180.19

Undervalued PE

7.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

51.16

Current EV/EBITDA

21.62

Overvalued EV/EBITDA

91.85

Undervalued EV/EBITDA

10.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

7.44

Current PS

1.87

Overvalued PS

12.67

Undervalued PS

2.20

Financials

Annual

Quarterly

FY2025Q1

YoY :

-7.59%

41.46M

Total Revenue

FY2025Q1

YoY :

+49.63%

-16.06M

Operating Profit

FY2025Q1

YoY :

+84.83%

-11.40M

Net Income after Tax

FY2025Q1

YoY :

+80.00%

-0.09

EPS - Diluted

FY2025Q1

YoY :

-129.27%

-976.00K

Free Cash Flow

FY2025Q1

YoY :

-10.33%

46.00

Gross Profit Margin - %

FY2025Q1

YoY :

+1122.22%

8.80

FCF Margin - %

FY2025Q1

YoY :

+100.00%

-27.50

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CTKB News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

16:41:09

Cytek Biosciences cuts FY25 revenue view to $196M-$210M from $204M-$212M

2025-05-08

16:39:46

Cytek Biosciences reports Q1 EPS (9c) vs. (5c) last year

2025-02-27 (ET)

2025-02-27

16:53:38

Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M

News

3.5

04-29Newsfilter

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

5.0

03-18Yahoo Finance

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

4.0

03-04Benzinga

Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8

People Also Watch

ORRF

Orrstown Financial Services Inc

Castle Biosciences Inc

Foresight Autonomous Holdings Ltd

NGL Energy Partners LP

3.310

USD

-0.90%

FAQ

What is Cytek Biosciences Inc (CTKB) stock price today?

The current price of CTKB is 2.67 USD — it has decreased -0.37 % in the last trading day.

CTKB

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CTKB News & Events

Events Timeline

News

People Also Watch

FAQ

What is Cytek Biosciences Inc (CTKB) stock price today?

What is Cytek Biosciences Inc (CTKB)'s business?

What is the price predicton of CTKB Stock?

What is Cytek Biosciences Inc (CTKB)'s revenue for the last quarter?

What is Cytek Biosciences Inc (CTKB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cytek Biosciences Inc (CTKB)'s fundamentals?

How many employees does Cytek Biosciences Inc (CTKB). have?

What is Cytek Biosciences Inc (CTKB) market cap?